Chandra Asri Pacific Clarifies 1.48% Stake in Prodia

Jakarta — Prajogo Pangestu’s company, PT Chandra Asri Pacific Tbk (TPIA), has spoken out regarding its ownership of shares in PT Prodia Widyahusada Tbk (PRDA). This clarification was delivered after shareholder data published by KSEI showed TPIA held 13.89 million shares, or approximately 1.48% of PRDA, as of May 2026. Chandra Asri Group’s Director of Human Resources & Corporate Affairs, Suryandi, explained that the purchase of PRDA shares in April 2026 was part of the company’s short-term investment portfolio management. According to him, the transaction is not related to any corporate action or strategic move by the company. “As a public company, we understand the market’s attention to every investment activity of the Company. However, we need to emphasise that the investment in PRDA shares is part of non-strategic financial portfolio management and is not related to expansion plans, acquisitions, strategic partnerships, or changes in Chandra Asri Group’s business focus,” Suryandi stated on Monday. He stressed that the investment in PRDA shares was carried out to optimise the company’s fund management. Therefore, the investment does not reflect a change in Chandra Asri Group’s business direction or growth strategy. The company affirmed that its share ownership in PRDA does not indicate any involvement of Chandra Asri Group in the operational activities of the healthcare service company. Furthermore, TPIA is not involved in the management or business decision-making at Prodia. According to Suryandi, Chandra Asri Group remains focused on executing the long-term growth strategy established by the company. In implementing this strategy, the company prioritises the principles of transparency and good corporate governance. As a publicly listed company, Chandra Asri Group stated that all corporate activities are conducted in accordance with Good Corporate Governance (GCG) principles and applicable capital market regulations. The company also ensures that any material information will be conveyed through information disclosure mechanisms to regulators and the public. “Transparency and good corporate governance are an important part of our commitment to shareholders, investors, and all stakeholders. Therefore, we will continue to ensure that every piece of information conveyed to the public is accurate, relevant, and in accordance with applicable regulations,” Suryandi added. This move coincides with the planned Initial Public Offering (IPO) of PRDA’s subsidiary, PT Prodia Diagnostic Line Tbk (PRDL). The company is offering up to 522.9 million new shares, equivalent to 30% of the issued and fully paid-up capital post-IPO. In the preliminary prospectus published on 18 June 2026, PRDL set an offering price range of Rp100-Rp120 per share. Thus, the company has the potential to raise fresh funds of up to Rp62.75 billion from this corporate action.